Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 44

1.

Increase in negative charge of 68Ga/chelator complex reduces unspecific hepatic uptake but does not improve imaging properties of HER3-targeting affibody molecules.

Rinne SS, Dahlsson Leitao C, Gentry J, Mitran B, Abouzayed A, Tolmachev V, Ståhl S, Löfblom J, Orlova A.

Sci Rep. 2019 Nov 27;9(1):17710. doi: 10.1038/s41598-019-54149-3.

2.

Selection of an optimal macrocyclic chelator improves the imaging of prostate cancer using cobalt-labeled GRPR antagonist RM26.

Mitran B, Thisgaard H, Rinne S, Dam JH, Azami F, Tolmachev V, Orlova A, Rosenström U.

Sci Rep. 2019 Nov 19;9(1):17086. doi: 10.1038/s41598-019-52914-y.

3.

Comparative evaluation of affibody- and antibody fragments-based CAIX imaging probes in mice bearing renal cell carcinoma xenografts.

Garousi J, Huizing FJ, Vorobyeva A, Mitran B, Andersson KG, Leitao CD, Frejd FY, Löfblom J, Bussink J, Orlova A, Heskamp S, Tolmachev V.

Sci Rep. 2019 Oct 17;9(1):14907. doi: 10.1038/s41598-019-51445-w.

4.

Bispecific GRPR-Antagonistic Anti-PSMA/GRPR Heterodimer for PET and SPECT Diagnostic Imaging of Prostate Cancer.

Mitran B, Varasteh Z, Abouzayed A, Rinne SS, Puuvuori E, De Rosa M, Larhed M, Tolmachev V, Orlova A, Rosenström U.

Cancers (Basel). 2019 Sep 14;11(9). pii: E1371. doi: 10.3390/cancers11091371.

5.

Evaluation of Tumor-Targeting Properties of an Antagonistic Bombesin Analogue RM26 Conjugated with a Non-Residualizing Radioiodine Label Comparison with a Radiometal-Labelled Counterpart.

Oroujeni M, Abouzayed A, Lundmark F, Mitran B, Orlova A, Tolmachev V, Rosenström U.

Pharmaceutics. 2019 Aug 2;11(8). pii: E380. doi: 10.3390/pharmaceutics11080380.

6.

Synthesis and Preclinical Evaluation of Radio-Iodinated GRPR/PSMA Bispecific Heterodimers for the Theranostics Application in Prostate Cancer.

Abouzayed A, Yim CB, Mitran B, Rinne SS, Tolmachev V, Larhed M, Rosenström U, Orlova A.

Pharmaceutics. 2019 Jul 23;11(7). pii: E358. doi: 10.3390/pharmaceutics11070358.

7.

Selection of the optimal macrocyclic chelators for labeling with 111In and 68Ga improves contrast of HER2 imaging using engineered scaffold protein ADAPT6.

von Witting E, Garousi J, Lindbo S, Vorobyeva A, Altai M, Oroujeni M, Mitran B, Orlova A, Hober S, Tolmachev V.

Eur J Pharm Biopharm. 2019 Jul;140:109-120. doi: 10.1016/j.ejpb.2019.05.008. Epub 2019 May 10.

8.

Trastuzumab cotreatment improves survival of mice with PC-3 prostate cancer xenografts treated with the GRPR antagonist 177 Lu-DOTAGA-PEG2 -RM26.

Mitran B, Rinne SS, Konijnenberg MW, Maina T, Nock BA, Altai M, Vorobyeva A, Larhed M, Tolmachev V, de Jong M, Rosenström U, Orlova A.

Int J Cancer. 2019 Dec 15;145(12):3347-3358. doi: 10.1002/ijc.32401. Epub 2019 May 23.

9.

Improved contrast of affibody-mediated imaging of HER3 expression in mouse xenograft model through co-injection of a trivalent affibody for in vivo blocking of hepatic uptake.

Rosestedt M, Andersson KG, Rinne SS, Leitao CD, Mitran B, Vorobyeva A, Ståhl S, Löfblom J, Tolmachev V, Orlova A.

Sci Rep. 2019 May 1;9(1):6779. doi: 10.1038/s41598-019-43145-2.

10.

Comparison of tumor‑targeting properties of directly and indirectly radioiodinated designed ankyrin repeat protein (DARPin) G3 variants for molecular imaging of HER2.

Vorobyeva A, Sсhulga A, Konovalova E, Güler R, Mitran B, Garousi J, Rinne S, Löfblom J, Orlova A, Deyev S, Tolmachev V.

Int J Oncol. 2019 Apr;54(4):1209-1220. doi: 10.3892/ijo.2019.4712. Epub 2019 Feb 11.

11.

Site-specific conjugation of recognition tags to trastuzumab for peptide nucleic acid-mediated radionuclide HER2 pretargeting.

Westerlund K, Vorobyeva A, Mitran B, Orlova A, Tolmachev V, Karlström AE, Altai M.

Biomaterials. 2019 May;203:73-85. doi: 10.1016/j.biomaterials.2019.02.012. Epub 2019 Feb 14.

12.

Molecular Design of HER3-Targeting Affibody Molecules: Influence of Chelator and Presence of HEHEHE-Tag on Biodistribution of 68Ga-Labeled Tracers.

Dahlsson Leitao C, Rinne SS, Mitran B, Vorobyeva A, Andersson KG, Tolmachev V, Ståhl S, Löfblom J, Orlova A.

Int J Mol Sci. 2019 Mar 2;20(5). pii: E1080. doi: 10.3390/ijms20051080.

13.

Optimization of HER3 expression imaging using affibody molecules: Influence of chelator for labeling with indium-111.

Rinne SS, Leitao CD, Mitran B, Bass TZ, Andersson KG, Tolmachev V, Ståhl S, Löfblom J, Orlova A.

Sci Rep. 2019 Jan 24;9(1):655. doi: 10.1038/s41598-018-36827-w.

14.

Comparative Evaluation of Two DARPin Variants: Effect of Affinity, Size, and Label on Tumor Targeting Properties.

Deyev S, Vorobyeva A, Schulga A, Proshkina G, Güler R, Löfblom J, Mitran B, Garousi J, Altai M, Buijs J, Chernov V, Orlova A, Tolmachev V.

Mol Pharm. 2019 Mar 4;16(3):995-1008. doi: 10.1021/acs.molpharmaceut.8b00922. Epub 2019 Feb 8.

PMID:
30608701
15.

Comparative evaluation of dimeric and monomeric forms of ADAPT scaffold protein for targeting of HER2-expressing tumours.

Garousi J, Lindbo S, Borin J, von Witting E, Vorobyeva A, Oroujeni M, Mitran B, Orlova A, Buijs J, Tolmachev V, Hober S.

Eur J Pharm Biopharm. 2019 Jan;134:37-48. doi: 10.1016/j.ejpb.2018.11.004. Epub 2018 Nov 5.

16.

Affibody‑mediated imaging of EGFR expression in prostate cancer using radiocobalt‑labeled DOTA‑ZEGFR:2377.

Mitran B, Andersson KG, Lindström E, Garousi J, Rosestedt M, Tolmachev V, Ståhl S, Orlova A, Löfblom J.

Oncol Rep. 2019 Jan;41(1):534-542. doi: 10.3892/or.2018.6792. Epub 2018 Oct 15.

PMID:
30320363
17.

Preclinical Evaluation of [68Ga]Ga-DFO-ZEGFR:2377: A Promising Affibody-Based Probe for Noninvasive PET Imaging of EGFR Expression in Tumors.

Oroujeni M, Garousi J, Andersson KG, Löfblom J, Mitran B, Orlova A, Tolmachev V.

Cells. 2018 Sep 18;7(9). pii: E141. doi: 10.3390/cells7090141.

18.

Radionuclide imaging of VEGFR2 in glioma vasculature using biparatopic affibody conjugate: proof-of-principle in a murine model.

Mitran B, Güler R, Roche FP, Lindström E, Selvaraju RK, Fleetwood F, Rinne SS, Claesson-Welsh L, Tolmachev V, Ståhl S, Orlova A, Löfblom J.

Theranostics. 2018 Aug 7;8(16):4462-4476. doi: 10.7150/thno.24395. eCollection 2018.

19.

Affibody-derived drug conjugates: Potent cytotoxic molecules for treatment of HER2 over-expressing tumors.

Altai M, Liu H, Ding H, Mitran B, Edqvist PH, Tolmachev V, Orlova A, Gräslund T.

J Control Release. 2018 Oct 28;288:84-95. doi: 10.1016/j.jconrel.2018.08.040. Epub 2018 Aug 30.

PMID:
30172673
20.

Comparative Evaluation of Radioiodine and Technetium-Labeled DARPin 9_29 for Radionuclide Molecular Imaging of HER2 Expression in Malignant Tumors.

Vorobyeva A, Bragina O, Altai M, Mitran B, Orlova A, Shulga A, Proshkina G, Chernov V, Tolmachev V, Deyev S.

Contrast Media Mol Imaging. 2018 Jun 6;2018:6930425. doi: 10.1155/2018/6930425. eCollection 2018.

Supplemental Content

Loading ...
Support Center